Two-Day Rally Continues Wockhardt shares jumped 6%, extending a massive 27% surge in two days after US FDA formally accepted the New Drug Application for Zaynich
Market Cap Soars by ₹5,400 Crore The stock hit ₹1,566.90 intraday, boosting Wockhardt’s market capitalisation to ₹25,493 crore during the sharp two-day rally
Zaynich Targets Severe Infections Zaynich is designed to treat complicated urinary tract infections caused by multi-drug-resistant gram-negative bacteria, addressing serious unmet medical needs
Historic First for Indian Pharma Wockhardt becomes the first Indian pharmaceutical company to have a New Chemical Entity NDA filed and accepted by the US FDA
Fast Track & Priority Review The FDA granted fast-track status to Zaynich, ensuring priority review due to its potential life-saving impact in critical infection cases